The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News

China Approves Market Launch Of Brain-computer Interface Medical Device in World First

China's drug regulator said on Friday that it has given the nod for a brain-computer interface (BCI) system ⁠that helps restore hand-movement ability to be sold, the world's...

Why Aren’t Canadians Getting Enough Sleep?

The change to daylight saving time and the marking of World Sleep Day call attention to the factors that contribute to sleep deficits among Canadians.

Single IV Ketamine Promising for Depression in MCI

Ketamine is well-tolerated in older adults with both mild cognitive impairment and depression and associated with improved depression scores, a new study shows.

Late Complications Common After CVT, Even After Recovery

Although a majority of patients with cerebral venous sinus thrombosis achieve independence, 1 in 3 may develop delayed complications such as seizures, a study shows.

Activity Trackers May Predict MS Progression

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

WHO Warns Of Health Risks From 'Black Rain' in Iran

The World Health Organization warned on Tuesday that the 'black rain' and toxic compounds in the air in Iran after strikes on ⁠oil facilities could cause respiratory problems.

Todays Updates

Telemedicine Not Reaching Rural Psychiatric Patients

Telemedicine use is not associated with a substantial increase in mental health treatment among patients in rural, low-access, or distant communities, a new study shows.

Shorter but More Intense RT: A Better Option for HNSCC?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Todays Updates

Telemedicine Not Reaching Rural Psychiatric Patients

Telemedicine use is not associated with a substantial increase in mental health treatment among patients in rural, low-access, or distant communities, a new study shows.

Shorter but More Intense RT: A Better Option for HNSCC?

A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.

New Nanoparticles Can Destroy Undruggable Cancer Proteins

Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.

Adjuvant Tx May Boost Survival in Bilateral Breast Cancer

A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.

Latest News

China's drug regulator said on Friday that it has given the nod for a brain-computer interface (BCI) system ⁠that helps restore hand-movement ability to be sold, the world's...

The change to daylight saving time and the marking of World Sleep Day call attention to the factors that contribute to sleep deficits among Canadians.

Ketamine is well-tolerated in older adults with both mild cognitive impairment and depression and associated with improved depression scores, a new study shows.

Although a majority of patients with cerebral venous sinus thrombosis achieve independence, 1 in 3 may develop delayed complications such as seizures, a study shows.

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

The World Health Organization warned on Tuesday that the 'black rain' and toxic compounds in the air in Iran after strikes on ⁠oil facilities could cause respiratory problems.

News All Time

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Trials Offer Mixed Results on BTK Potential for PPMS

Promising findings for fenebrutinib and disappointing results for tolebrutinib offer mixed results on the potential of BTK inhibitors for primary progressive MS.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

What If We’ve Been Wrong About How ADHD Drugs Work?

A new analysis of brain scans from nearly 12,000 children could change the way clinicians and researchers think about how stimulants for ADHD work.

Wrist-Worn Sleep Trackers Predict Depression Relapse

Actigraphy data show irregular sleep-wake rhythms nearly double the risk for relapse in individuals with remitted major depressive disorder.

Vertebral Fractures Tied to Lower Lung Volumes in ILD

Thoracic vertebral fractures may worsen lung function and reduce lung volumes in patients with interstitial lung disease.

Japan Endorses IPS-derived Treatment for Parkinson's

A panel of specialists has endorsed an iPS cell-derived treatment for Parkinson's ⁠disease, paving the ‌way for the world's first medical products based on the technology.

Cognitive Training May Lower Dementia Risk 20 Years Later

In a long-running RCT, older adults who completed adaptive speed-of-processing training with boosters were less likely to develop dementia — a benefit not seen with memory or reasoning training.

FDA Okays Pitolisant for Cataplexy in Pediatric Narcolepsy

With this new indication, pitolisant is now approved to treat excessive daytime sleepiness, cataplexy, or both, in patients aged 6 years or older with narcolepsy.

Lifelong Cognitive Enrichment Tied to Lower Dementia Risk

Lifelong cognitive enrichment is linked to a lower risk for Alzheimer's disease, delayed onset, and better cognitive function despite brain pathology.

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

Interpreting the DAWN Trial: Where Anti-CD38 Therapy May Fit in NMOSD Care Marco Meglio

Neurologists Michael Levy, MD, PhD, and Fu-Dong Shi, MD, PhD, discuss the rationale, design, and clinical implications of the phase 3 DAWN trial evaluating daratumumab in aquaporin-4–positive NMOSD.

Recommended News For You

FDA Expands Approval of Osimertinib in Lung Cancer

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer

Standardized criteria for amino acid PET imaging could improve diagnosis and treatment of brain metastases

Leukemia cells evade treatment by reshaping their mitochondria, researchers discover

Metastatic Cancer 'Thrivers'; Celebrity Cancer Diagnoses; 'Would He Have Lived?'

More cancer cases in areas where incarceration rates are high: Study

Recommended Articles For You

Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer 

Exploring the Effects of Radiation Therapy on Cystitis: A Journey to Better Health 

How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education? 

Vaccines that can help prevent cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

2.

Discovery of a new biomarker for early detection of bladder cancer in both dogs and humans

3.

Error on the MGUS-Autoimmune Disease Association.

4.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

5.

Trump Issues Gag Order for CDC, FDA; Stalled Hearing for RFK Jr.; Sex After Cancer

1.

Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025

2.

Beyond the Blood: Expanding CAR T-Cell Therapy to Solid Tumors- A New Era of Precision Oncology

3.

Cancer Rates on the Rise: What Can We Do to Stop It?

4.

KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer

5.

The Miracle of Thyrogen Injection: A New Hope for Thyroid Cancer Treatment

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II

3.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases

4.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion

5.

Updates on Standard V/S High Risk Myeloma Treatment


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot